Seres Therapeutics (MCRB) Competitors $14.07 -0.01 (-0.07%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.80 +0.73 (+5.22%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. ATYR, SIGA, TRML, CGEM, MBX, RZLT, KMDA, TERN, RGNX, and SVRAShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include aTyr Pharma (ATYR), Siga Technologies (SIGA), Tourmaline Bio (TRML), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), Rezolute (RZLT), Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), and Savara (SVRA). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Its Competitors aTyr Pharma Siga Technologies Tourmaline Bio Cullinan Therapeutics MBX Biosciences Rezolute Kamada Terns Pharmaceuticals REGENXBIO Savara Seres Therapeutics (NASDAQ:MCRB) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership. Which has more risk & volatility, MCRB or ATYR? Seres Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Which has higher earnings & valuation, MCRB or ATYR? Seres Therapeutics has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.32M0.97$140K-$4.60-3.06aTyr PharmaN/AN/A-$64.02M-$0.81-7.40 Does the media refer more to MCRB or ATYR? In the previous week, aTyr Pharma had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for aTyr Pharma and 1 mentions for Seres Therapeutics. aTyr Pharma's average media sentiment score of 0.42 beat Seres Therapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer MCRB or ATYR? Seres Therapeutics presently has a consensus price target of $73.67, suggesting a potential upside of 423.57%. aTyr Pharma has a consensus price target of $20.20, suggesting a potential upside of 237.23%. Given Seres Therapeutics' higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than aTyr Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is MCRB or ATYR more profitable? aTyr Pharma's return on equity of -87.09% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A -41,084.76% -55.87% aTyr Pharma N/A -87.09%-64.77% Do insiders and institutionals hold more shares of MCRB or ATYR? 59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryaTyr Pharma beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.86M$2.93B$5.53B$9.41BDividend YieldN/A2.48%3.76%4.04%P/E Ratio-3.0619.8828.2619.78Price / Sales0.97293.75412.9994.60Price / CashN/A41.8435.8558.18Price / Book8.747.678.115.65Net Income$140K-$55.28M$3.25B$257.97M7 Day Performance11.93%4.87%1.63%3.74%1 Month Performance90.14%13.14%7.62%11.95%1 Year Performance-42.57%3.51%32.74%19.22% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics2.897 of 5 stars$14.07-0.1%$73.67+423.6%-42.6%$122.86M$126.32M-3.06330News CoverageGap UpATYRaTyr Pharma2.2397 of 5 stars$5.53+4.3%$20.20+265.3%+265.2%$492.17M$230K-6.8353News CoverageGap UpHigh Trading VolumeSIGASiga Technologies1.9894 of 5 stars$6.86+1.3%N/A-29.2%$490.08M$138.72M10.2440TRMLTourmaline Bio1.9813 of 5 stars$18.96+5.5%$49.33+160.2%+25.6%$486.99MN/A-5.9144News CoveragePositive NewsCGEMCullinan Therapeutics1.9285 of 5 stars$7.87+2.2%$30.00+281.2%-58.8%$464.41MN/A-2.7030MBXMBX Biosciences2.4153 of 5 stars$13.87+6.4%$37.50+170.4%N/A$463.59MN/A0.0036News CoverageAnalyst ForecastRZLTRezolute2.4206 of 5 stars$5.32+1.1%$11.83+122.4%+19.2%$454.97MN/A-4.6340News CoverageKMDAKamada3.8276 of 5 stars$7.78+0.4%$13.00+67.1%+28.9%$447.39M$167.24M26.83360Positive NewsTERNTerns Pharmaceuticals3.5921 of 5 stars$5.11+4.3%$15.63+205.8%-33.5%$446.31MN/A-4.6940RGNXREGENXBIO3.7745 of 5 stars$8.70+0.2%$31.63+263.5%-35.1%$436.39M$83.33M-2.80370News CoverageAnalyst RevisionSVRASavara2.1427 of 5 stars$2.51+5.0%$5.60+123.1%-49.4%$433.83MN/A-5.2320News CoveragePositive News Related Companies and Tools Related Companies ATYR Competitors SIGA Competitors TRML Competitors CGEM Competitors MBX Competitors RZLT Competitors KMDA Competitors TERN Competitors RGNX Competitors SVRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts